Aktien, die jeden Tag teurer werden, bzw. die weggekauft werden wie warme Semmeln.
Eine dieser fantastischen Stories ist NVGN.
Diese australische Firma gehört im Moment zum heissesten Play an der Nasdaq überhaupt.
Die Nachrichtenlage ist hervorragend, der Chart auch.
chart.bigcharts.com/bc3/quickchart/...58&mocktick=1&rand=8474" style="max-width:560px" >
Australian Patent Granted to Novogen Covering its Skin Repair Compound NV-07a Patent Means Novogen Now Has Protection in the U.S. and Australia
STAMFORD, Conn., Jan 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- The
Australian patent has been granted to Novogen (Nasdaq: NVGN) for its topical
skin repair compound, NV-07a, covering protection of the skin from sun-induced
immunosuppression and UV-induced damage.
The effects of sun damage to the skin are major medical and cosmetic issues in
Australia. NV-07a has been developed to repair the skin after damage caused by
prolonged exposure to sunlight.
Changes in the skin due to prolonged exposure to sunlight can lead to structural
damage resulting in wrinkling and photo-aging. These changes can also cause
pronounced suppression of the normal skin immune activity and at the same time
damage to the DNA of skin cells.
Together, these effects predispose to the development of skin cancers.
NV-07a has been shown to restore immune function and inhibit the DNA changes
that may occur, even when used after sun exposure.
Professor Alan Husband, Novogen's Research Director, said while sun block creams
had been the mainstay of skin protection from acute effects of sun exposure,
they had not reduced the incidence of certain types of skin cancer.
"We have demonstrated in human studies and previously in animals that topical
application of NV-07a after sun exposure can prevent these deleterious changes
in the skin and this is a technology which will revolutionize skin care
formulations," Professor Husband said.
Novogen has announced results from two human clinical trials in which
immunosuppression and ongoing DNA damage were both ameliorated in the skin of
human subjects who had been administered a topical skin cream containing NV-07a
after sun exposure.
Mr. Christopher Naughton, Novogen's CEO, said the Australian patent is a
valuable addition to the worldwide patenting programsurrounding NV-07a. The U.S.
patent was granted in late 2002, and further international patents are in
"NV-07a is an exciting commercial opportunity and its value is underwritten by
the success of our aggressive intellectual property and patenting strategy," he
Novogen coordinates and manages its international research and development
programs utilizing the expertise and clinical research capabilities of
universities and hospitals both in Australia and in key international locations.
Novogen's pharmaceutical drug discovery and development portfolio includes the
anti-cancer drug phenoxodiol, and the NV-04 cardiovascular drug program, both
undergoing human clinical trials. More information can be found atwww.novogen.com
CONTACT: Warren Lancaster of Novogen Limited, +1-203-327-1188, ext. 10, or David
Sheon, +1-202-518-6321, for Novogen Limited
SOURCE Novogen Limited